An advantage of IL-2 therapy is that recombinant human IL-2 is already available in the clinic as a therapeutic drug called Aldesleukin or Proleukin, for the treatment of malignant melanoma and renal cell carcinoma [69]. This evidence concerns the gene IL2 and hereditary clear cell renal cell carcinoma.